Literature DB >> 22202468

Eosinophilic inflammation in allergic rhinitis and nasal polyposis.

Aleksandar Perić1, Danilo Vojvodić, Biserka Vukomanović-Đurđević, Nenad Baletić.   

Abstract

On histopathological examination, nasal polyps and nasal mucosa in allergic rhinitis show different forms of pseudostratified respiratory epithelium, whereas the dominant characteristic of lamina propria is an eosinophilic infiltration. The aim of this study was to compare interleukin (IL)-5 and eosinophilic cationic protein (ECP) levels in the nasal fluid of 42 patients: 12 with allergic rhinitis and nasal septal deviation, 17 non-atopic patients with nasal polyposis, and 13 atopic nasal polyp patients were enrolled in this cross-sectional study. Nasal secretion samples were collected a few days before surgery. The levels of IL-5 were measured using flow cytometry and the ECP using a commercial ELISA kit. In addition, we counted eosinophils in hematoxylin-and-eosin-stained sections of all nasal polyp and all nasal mucosa samples taken from the inferior nasal turbinates during septoplasty. A significantly higher concentration of IL-5 was found in the nasal fluid of atopic patients with nasal polyposis than in non-atopic nasal polyp patients (p=0.025) and patients with allergic rhinitis (p=0.05). ECP was higher in atopic nasal polyp patients than in patients with allergic rhinitis (p<0.0001) and than in non-atopic nasal polyp patients (p<0.0001). Polyp eosinophils were higher in atopic' than in non-atopic patients (p<0.0001) and higher than in the mucosa of patients with allergic rhinitis (p<0.0001). These however had significantly more mucosal eosinophils than was found in the polyps of non-atopic patients' (p=0.025). ECP levels in nasal fluid and eosinophil counts in tissue specimens correlated well in all three groups of patients. Our study has shown that atopic nasal polyp patients have a higher level of eosinophilic inflammation than non-atopic patients with nasal polyps and patients with allergic rhinitis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22202468     DOI: 10.2478/10004-1254-62-2011-2120

Source DB:  PubMed          Journal:  Arh Hig Rada Toksikol        ISSN: 0004-1254            Impact factor:   1.948


  6 in total

1.  Determination of Serum IgE and Eosinophils as a Diagnostic Indicator in Allergic Rhinitis.

Authors:  Manuprita Sharma; Tanya Khaitan; Santosh Raman; Ritika Jain; Arpita Kabiraj
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-05-02

2.  Diesel exposure suppresses natural killer cell function and resolution of eosinophil inflammation: a randomized controlled trial of exposure in allergic rhinitics.

Authors:  Erica A Pawlak; Terry L Noah; Haibo Zhou; Claire Chehrazi; Carole Robinette; David Diaz-Sanchez; Loretta Müller; Ilona Jaspers
Journal:  Part Fibre Toxicol       Date:  2016-05-06       Impact factor: 9.400

3.  Hydrogen-rich saline attenuates eosinophil activation in a guinea pig model of allergic rhinitis via reducing oxidative stress.

Authors:  Shaoqing Yu; Chuanliang Zhao; Na Che; Lin Jing; Rongming Ge
Journal:  J Inflamm (Lond)       Date:  2017-01-13       Impact factor: 4.981

Review 4.  Platelet-Eosinophil Interactions As a Potential Therapeutic Target in Allergic Inflammation and Asthma.

Authors:  Sajeel A Shah; Clive P Page; Simon C Pitchford
Journal:  Front Med (Lausanne)       Date:  2017-08-08

5.  Xanthii Fructus inhibits allergic response in the ovalbumin-sensitized mouse allergic rhinitis model.

Authors:  Nam-Gil Gwak; Eun-Young Kim; Bina Lee; Jae-Hyun Kim; Yong-Seok Im; Ka-Yeon Lee; Chang Jun-Kum; Ho-Seok Kim; Hyun-Joo Cho; Hyuk-Sang Jung; Youngjoo Sohn
Journal:  Pharmacogn Mag       Date:  2015-10       Impact factor: 1.085

6.  IL-1RN VNTR, IL-2(-330), and IL-4 VNTR gene polymorphisms in patients with chronic rhinosinusitis with sinonasal polyposis

Authors:  Gökhan Kuran; Hüseyin Aslan; Süheyl Haytoğlu; Özge Özalp Yüreğir; Sevcan Tuğ Bozdoğan
Journal:  Turk J Med Sci       Date:  2019-10-24       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.